Viewing nowPioglitazone 15 mg Tablet (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 200703877 · Notified 2007.04.03 · Insurance code 645903420
Improvement of glycemic control in type 2 diabetes
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It is taken in conjunction with diet and exercise therapy and can be administered alone or in combination with other hypoglycemic agents. If blood sugar control is difficult, it may be used alongside sulfonylureas, metformin, and insulin. Additionally, nutritional counseling, weight loss, and exercise therapy should also be implemented, and all these efforts are crucial for the initial treatment and maintenance of drug therapy effectiveness. This medication effectively improves blood sugar control in patients with type 2 diabetes.
This medicine is administered orally once daily, with or without food. Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, this medicine should be administered for an adequate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that the patient's glycemic control does not worsen. 1. Monotherapy This medicine may be started at 15 mg of pioglitazone once daily as monotherapy in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide a sufficient effect, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be coadministered with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dosage regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be coadministered with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dosage regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be coadministered with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, if a patient receiving this medicine with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be made individually according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Patients with renal impairment under General Precautions). Treatment with this medicine should not be initiated if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) (see Effects on the liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on administering this medicine in combination therapy with other thiazolidinediones.
Use is not recommended in children under 18 years of age because there is no experience with its use in this age group.
This medication is used to treat type 2 diabetes and works with insulin to control blood sugar levels. This medication may put stress on the heart and should not be administered to patients with heart failure or a history of heart failure. During treatment, careful observation for symptoms of heart failure such as weight gain, swelling, and shortness of breath is necessary. If symptoms occur, immediate consultation with a physician for appropriate action is required. Patients with active bladder cancer or a history of bladder cancer should also not use this medication. It is contraindicated in patients with severe liver or kidney impairment. Women who are pregnant or may become pregnant should not take this medication, and premenopausal women should use appropriate contraception to prevent pregnancy while taking this medication. This medication carries a risk of hypoglycemia, so it is crucial to be well-informed about hypoglycemic symptoms, especially when taken together with insulin or other hypoglycemic agents, and to respond immediately if they occur. Regular liver function tests and blood sugar tests should be conducted throughout treatment, and if symptoms of liver damage (e.g., fatigue, loss of appetite, jaundice) occur, the physician should be notified immediately. If sudden weight gain or severe swelling occurs during the course of this medication, it should be reported to a doctor. Elderly patients or those with impaired kidney or liver function should use this medication more cautiously and be closely monitored for the possibility of adverse effects. Although special symptoms may not appear in case of overdose, appropriate treatment should be administered based on clinical symptoms. This medication has not been shown to be safe and effective in children, so it is not recommended for use in this age group. While taking this medication, there may be interactions with other medications, so all medications being taken should be reported to a doctor or pharmacist. Lastly, this medication should be kept out of reach of children and stored in its original container to maintain its quality.
congestive heart failure, fluid retention, edema, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, lumbar pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular predisposition, worsening of congestive heart failure, emergency room visits due to congestive heart failure, liver failure, diabetic macular edema with decreased vision, liver damage, decreased hemoglobin, elevated serum ALT, elevated serum bilirubin, increased serum creatinine, dizziness, loss of appetite, constipation, upper abdominal pain, chest discomfort, fatigue, weakness, dyspepsia, nausea, dyspnea, itching, chest unease, tremors, chills, gastrointestinal disease, epigastric discomfort, numbness, muscle rigidity, head discomfort, worsening of liver disease, hives, eczema, arthralgia, knee abnormalities, arm weakness syndrome, proteinuria, anxiety, insomnia, drowsiness, simple herpes, visual blur, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, heart failure, fracture
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's efficacy and safety for an extended period.
White to grayish-white, convex cylindrical tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.